|Articles|June 19, 2017

Clinical Ink and Integron Partner to Streamline IoT-enabled Clinical Trials

Clinical Ink, provider of eSource and patient engagement technologies, and Integron, provider of managed services for the connected health and Internet of Things (IoT) industry, announced a partnership to extent Clinical Ink's capabilites in mobile device and sensor deployment, in order to engage and collect data from patients in clinical trials.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

September 22nd, 2026

DPHARM 2026: The Patient Journey Gap That Study Design Still Hasn't Solved

In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why truly understanding the patient journey from beginning to end—and building that understanding into both study design and data collection tools—remains one of the industry's most important unfinished tasks.

September 22nd, 2026

ACT Brief: Patient-Site Interaction and Technology, AI Pilot Success Requires Discipline, and CagriSema Beats Lilly Drug

In today's ACT Brief, we examine technology's real role in patient-site collaboration, why AI pilot failures stem from organization not innovation, and Novo's weight-loss drug results in competitive comparison.

September 21st, 2026

Moving Beyond Disappointing Pilots: Scaling Adoption of AI-Enablement in Drug Development

Most AI pilots in drug development fail not from poor technology but from lack of strategic prioritization, organizational readiness, integrated data infrastructure, and disciplined governance, making success dependent on business discipline rather than technical capability.

September 21st, 2026

DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites

In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't usability alone—it's making it easier for patients and sites to interact more effectively with each other.

September 21st, 2026

ACT Brief: Patient-Site Trust and AI Role, Platform Approach to Scale, Gene Therapy for Pediatric Disease

In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.

September 18th, 2026

DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now

In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.

Scaling AI in life sciences takes more than more tools, it takes a platform that connects workflows, data and governance. Credit: Stock.Adobe.com/Grispb.

September 18th, 2026

How a Platform Approach Can Scale AI’s Impact in Life Sciences

A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.

September 18th, 2026

ACT Brief: Patient Voice as Methodology, AI System Bottlenecks, Regulatory Convergence on Patient Input

In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.